Regulatory Post-Marketing Surveillance Study for Brolucizumab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
Eligibility criteria
Qualifiers
Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information
Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent)
Disqualifiers
Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation.
Patients participating in other investigational drug trial
Trial design
Treatments tested in this trial
- brolucizumab
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov